These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36442805)

  • 41. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Gill K; Servati N; Flahive J; Fraielli K
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events.
    Alexopoulos D; Stavrou K; Koniari I; Gkizas V; Perperis A; Kontoprias K; Vogiatzi C; Bampouri T; Xanthopoulou I
    Thromb Haemost; 2014 Sep; 112(3):551-7. PubMed ID: 24990396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
    Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG
    JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects.
    De Filippo O; D'Ascenzo F; Raposeiras-Roubin S; Abu-Assi E; Peyracchia M; Bocchino PP; Kinnaird T; Ariza-Solé A; Liebetrau C; Manzano-Fernández S; Boccuzzi G; Henriques JPS; Templin C; Wilton SB; Omedè P; Velicki L; Xanthopoulou I; Correia L; Cerrato E; Rognoni A; Fabrizio U; Nuñez-Gil I; Iannaccone M; Montabone A; Taha S; Fujii T; Durante A; Song X; Gili S; Magnani G; Varbella F; Kawaji T; Blanco PF; Garay A; Quadri G; Alexopoulos D; Caneiro Queija B; Huczek Z; Cobas Paz R; González Juanatey JR; Cespón Fernández M; Nie SP; Muñoz Pousa I; Kawashiri MA; Gallo D; Morbiducci U; Conrotto F; Montefusco A; Dominguez-Rodriguez A; López-Cuenca A; Cequier A; Iñiguez-Romo A; Usmiani T; Rinaldi M; De Ferrari GM
    Eur Heart J Cardiovasc Pharmacother; 2020 Jan; 6(1):31-42. PubMed ID: 31511896
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ticagrelor vs Prasugrel in a Contemporary Real-World Cohort Undergoing Percutaneous Coronary Intervention.
    Koshy AN; Giustino G; Sartori S; Kyaw H; Yadav M; Zhang Z; Hooda A; Farooq A; Krishnamoorthy P; Sweeny JM; Khera S; Serrao GW; Sharma R; Suleman J; Dangas G; Kini AS; Mehran R; Sharma SK
    JACC Cardiovasc Interv; 2022 Nov; 15(22):2270-2280. PubMed ID: 36423970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy.
    Bongiovanni D; Schreiner N; Gosetti R; Mayer K; Angiolillo DJ; Sibbing D; Holdenrieder S; Anetsberger A; von Scheidt M; Schunkert H; Laugwitz KL; Schüpke S; Kastrati A; Fegers-Wustrow I; Bernlochner I
    Arterioscler Thromb Vasc Biol; 2023 Feb; 43(2):e83-e93. PubMed ID: 36546322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome.
    Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C
    J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of Postdischarge Bleeding From Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Among US Black and White Adults.
    Heindl B; Clarkson S; Parcha V; Dillon C; Narayan R; Usifo E; Hillegass W; Irvin MR; Arora P; Zhai G; Beasley M; Limdi N
    J Am Heart Assoc; 2022 Sep; 11(18):e024412. PubMed ID: 36073636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effectiveness and safety of prasugrel versus ticagrelor following percutaneous coronary intervention: An observational study.
    Belviso N; Aronow HD; Wyss R; Barbour M; Zhang Y; Wen X; Kogut S
    Pharmacotherapy; 2021 Jun; 41(6):515-525. PubMed ID: 33932252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Fong LCW; Lee NHC; Yan AT; Ng MY
    Cardiology; 2022; 147(1):1-13. PubMed ID: 34743081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
    Aradi D; Gross L; Trenk D; Geisler T; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Ruzsa Z; Ungi I; Rizas KD; May AE; Mügge A; Zeiher AM; Holdt L; Huber K; Neumann FJ; Koltowski L; Huczek Z; Hadamitzky M; Massberg S; Sibbing D
    Eur Heart J; 2019 Jun; 40(24):1942-1951. PubMed ID: 31226213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contemporary Use of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A GRACE Risk Score Stratification-Based Analysis in a Large-Scale, Real-World Study From China.
    Qiu M; Na K; Qi Z; Zhou H; Li P; Xu K; Wang B; Liu H; Li J; Li Y; Han Y
    Mayo Clin Proc; 2023 Jul; 98(7):1021-1032. PubMed ID: 37419570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial.
    Park DW; Kwon O; Jang JS; Yun SC; Park H; Kang DY; Ahn JM; Lee PH; Lee SW; Park SW; Choi SW; Lee SG; Yoon HJ; Ahn T; Kim MH; Nah DY; Lee SY; Chae JK; Park SJ;
    Circulation; 2019 Dec; 140(23):1865-1877. PubMed ID: 31553203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel.
    Aytekin A; Scalamogna M; Coughlan JJ; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Witzenbichler B; Hochholzer W; Sibbing D; Angiolillo DJ; Hemetsberger R; Tölg R; Valina C; Müller A; Kufner S; Liebetrau C; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Cassese S
    Clin Res Cardiol; 2024 Jul; 113(7):1060-1069. PubMed ID: 38740722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study.
    Patti G; D'Ascenzo F; De Filippo O; Bruno F; Leonardi S; Chieffo A; Iannaccone M; Liebetrau C; Manzano-Fernández S; Gallone G; Omedè P; Cerrato E; Kinnaird T; Conrotto F; Piroli F; Henriques JPS; Wańha W; Elia E; Dominguez-Rodriguez A; Raposeiras-Roubin S; Abu-Assi E; De Ferrari GM;
    Eur Heart J Qual Care Clin Outcomes; 2022 Nov; 8(8):881-891. PubMed ID: 35022719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes.
    Ndrepepa G; Neumann FJ; Menichelli M; Bernlochner I; Richardt G; Wöhrle J; Witzenbichler B; Mayer K; Cassese S; Gewalt S; Xhepa E; Kufner S; Sager HB; Joner M; Ibrahim T; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
    J Am Heart Assoc; 2021 Nov; 10(22):e021418. PubMed ID: 34779234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.